Search

Your search keyword '"Amylin Pharmaceuticals Inc."' showing total 5 results
Start Over Descriptor "Amylin Pharmaceuticals Inc." Region pennsylvania
5 results on '"Amylin Pharmaceuticals Inc."'

1. BYDUREON(tm) Was Associated with Significant and Sustained Glycemic Control at Four Years.

Subjects
TYPE 2 diabetes treatment, CLINICAL trials, COMPARATIVE studies, CONFERENCES & conventions
Abstract

The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trial of BYDUREON for the treatment of type 2 diabetes. It mentions that the efficacy of once-weekly treatment BYDUREON and twice-daily BYETTA was compared which revealed that BYDUREON controls glycemic level more efficiently. It further informs that the results were presented at the Scientific Sessions of the American Diabetes Association in Philadelphia, Pennsylvania.

Published
2012

2. BYETTA(r) Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl(r) in Patients with Type 2 Diabetes.

Subjects
TYPE 2 diabetes treatment, CLINICAL trials, COMPARATIVE studies, CONFERENCES & conventions
Abstract

The article informs that Amylin Pharmaceuticals Inc. has released the results from its comparative clinical trial of BYETTA and Amaryl for the treatment of type 2 diabetes. It mentions that BYETTA resulted in glycemic durability, weight loss and reduced risk of hypoglycemia. It further informs that the results were presented at the Scientific Sessions of the American Diabetes Association in Philadelphia, Pennsylvania.

Published
2012

3. Once-Weekly BYDUREON(tm) Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir(r) in Type 2 Diabetes.

Subjects
TYPE 2 diabetes treatment, CLINICAL trials, COMPARATIVE studies, CONFERENCES & conventions
Abstract

The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trials of BYDUREON and Levemir for the treatment of type 2 diabetes. A comparative study revealed that BYDUREON is a once weekly treatment which is more efficient in controlling glucose level and reducing weight. It further informs that the results were presented at the Scientific Sessions of the American Diabetes Association which was held in Philadelphia, Pennsylvania.

Published
2012

4. SYMLIN(r) Use Helped Patients with Type 2 or Type 1 Diabetes Achieve More Time in Normal Glucose Range.

Subjects
TREATMENT of diabetes, COMBINATION drug therapy, INSULIN, AMYLIN, CONFERENCES & conventions
Abstract

The article informs that Amylin Pharmaceuticals Inc. has released the results from its clinical studies of SYMLIN for the treatment of diabetes. It mentions that SYMLIN is a synthetic analogue of human amylin which is administered in combination with insulin. It further informs that the company has presented the results at the Scientific Sessions of the American Diabetes Association which was held in Philadelphia, Pennsylvania.

Published
2012

5. BYDUREON(tm) Improved A1C, Fasting Glucose, Pulse Pressure and Weight Regardless of Baseline Body Weight in Patients with Type 2 Diabetes.

Subjects
TYPE 2 diabetes treatment, CLINICAL trials, EXENATIDE, CONFERENCES & conventions
Abstract

The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC have released the results from its clinical trial of BYDUREON for the treatment of type 2 diabetes. It mentions that BYDUREON is a once-weekly formulation of exenatide which has been approved by the U.S. Food and Drug Administration. It further informs that the companies have presented the results at the Scientific Sessions of the American Diabetes Association which was held in Philadelphia, Pennsylvania.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results